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Abstract
Background: Adverse drug reactions (ADRs) contribute to ill-health or life-threatening outcomes of therapy during
management of infectious diseases. The exposure to anti-malarial and use of mobile phone technology to report
ADRs following drug exposures were investigated in Sagamu - a peri-urban community in Southwest Nigeria.
Methods: Purchase of medicines was actively monitored for 28 days in three Community Pharmacies (CP) and four
Patent and Proprietary Medicine Stores (PPMS) in the community. Information on experience of ADRs was obtained
by telephone from 100 volunteers who purchased anti-malarials during the 28-day period.
Results and Discussion: A total of 12,093 purchases were recorded during the period. Antibiotics, analgesics,
vitamins and anti-malarials were the most frequently purchased medicines. A total of 1,500 complete courses of
anti-malarials were purchased (12.4% of total purchases); of this number, purchases of sulphadoxine-pyrimethamine
(SP) and chloroquine (CQ) were highest (39.3 and 25.2% respectiuvely). Other anti-malarials purchased were
artesunate monotherapy (AS) - 16.1%, artemether-lumefantrine (AL) 10.0%, amodiaquine (AQ) - 6.6%, quinine (QNN)
- 1.9%, halofantrine (HF) - 0.2% and proguanil (PR) - 0.2%. CQ was the cheapest (USD 0.3) and halofantrine the
most expensive (USD 7.7). AL was 15.6 times ($4.68) more expensive than CQ. The response to mobile phone
monitoring of ADRs was 57% in the first 24 hours (day 1) after purchase and decreased to 33% by day 4.
Participants in this monitoring exercise were mostly with low level of education (54%).
Conclusion: The findings from this study indicate that ineffective anti-malaria medicines including monotherapies
remain widely available and are frequently purchased in the study area. Cost may be a factor in the continued use
of ineffective monotherapies. Availability of a toll-free telephone line may facilitate pharmacovigilance and follow
up of response to medicines in a resource-poor setting.
Background
Infection with malaria parasites remains one of the lead-
ing causes of hospital visits in Nigeria. Half of the esti-
mated population of 150 million experience at least one
malarial attack each year [1]. Early diagnosis and treat-
ment of malaria is well recognized as an effective means
of reducing morbidity and mortality of the infection [2].
Chloroquine (CQ) and sulphadoxine-pyrimethamine
were cheap and effective treatment for malaria intro-
duced in the middle of the 20th century. Unfortunately
emergence of Plasmodium falciparum resistance to
these drugs in South East Asia and eventual spread to
all malaria endemic areas compromised malaria treat-
ment of falciparum malaria in several malaria endemic
countries, including Nigeria [3] Artemisinin-based com-
bination therapy (ACT) was subsequently recommended
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by the WHO and introduced as part of a multi-compo-
nent strategy to mitigate the malaria burden [2-4]. As
ACT become more widely available and accessible, there
is a need to assess and document experience and occur-
rence of adverse drug reactions (ADRs) of these drugs
when used in larger populations or communities [5]. In
the industrialized economies of the northern hemi-
sphere, relatively robust health systems with capability
for systematic acquisition of post marketing data exist.
However, in sub-Saharan Africa, the treatment-seeking
pattern for maladies including malaria is complex and
impacted by the local health system, culture and
resources of the patient [6,7]. Anti-malarials are often
purchased from private retail sector without a confirmed
diagnosis of malaria. These vendors have been identified
as an important source of medicines and health care
close to people’s homes [8] and thus complement formal
health services. Information on the volume and types of
medicine purchased from these vendors and specifically
the level of exposure to anti-malarials is not available.
Establishment of a simple practical system for surveil-
lance from private drug outlets will be a useful tool for
pharmacovigilance and tracking possible adverse drug
reactions. With the recent introduction of ACT and dis-
tribution of millions of doses in sub-Saharan Africa,
there is concern about adequately monitoring ADR in
the population [9]. This study was designed to assess
exposure to anti-malarial drugs in Sagamu community
and to explore the use of widely available technology as
a tool to monitor ADRs following exposure of malaria
patients to antimalarial drugs.
Methods
Study setting
Sagamu, located 50 km north of Lagos is the seat of the
Sagamu Local Government Area, Ogun State in south-
west Nigeria. The town is spread over 614 Km2 (237/
Sqm) with an estimated population of 228,382. A large
proportion of the population commutes to the city of
Lagos daily for work or other commercial activities.
Malaria is highly endemic in the area, accounting for
most outpatient visits in the health facilities. Transmis-
sion occurs all year around with an upsurge in the rainy
season - June to September [10]. The community is
served by several schools, hospitals (Primary Health
Care Centers, Private and Tertiary Hospitals), banks and
hotels.
Selection of study centers
Study centers were identified and selected from the list
of registered pharmacies and Patent and Proprietary
Medicine Stores (PPMS) compiled by the Department of
Pharmaceutical Services, Ministry of Health, Ogun State.
There are 128 PPMS and 13 pharmacies listed in the
state’s official records. The patient load in these facilities
record average of 225 per day; (pharmacies, range 150-
400 per day; PPMS, 35-50 per day).
From the 141 drug outlets a sample size of seven
(three pharmacies and four PPMS) was determined at
confidence interval of 50% and confidence level of 95%
using Survey System sample size calculator http://www.
surveysystem.com/sscalc.htm. The specific facilities were
chosen using computer generated simple randomization
procedure.
The study was descriptive and prospective, and
involved active follow-up of sales of drugs in the
selected centres for a period of four weeks (28 days) to
determine the exposure to anti-malarial drug, measured
by the amount of drugs purchased within the period. A
drug-data chart was designed to capture information on
category of drugs purchased. The proportion of anti-
malarial of the different drugs purchased at the drug
retail outlets, which at the time of study were not
tracked by any active surveillance method, and sales per
week of the medicines were determined. The anti-malar-
ial drugs were classified to assess the drug use pattern
for the different anti-malarial drugs and the rate of pur-
chase between PPMS and the community pharmacies.
The retail prices of the different anti-malarial drugs in a
complete dosage pack were recorded.
The willingness of the buyers of the anti-malarial
drugs in this community to participate in pharmacovigi-
lance (PV), through a toll free mobile phone monitoring
of adverse drug reactions, was evaluated in a total of
100 subjects who presented at the study sites to pur-
chase anti-malarial drugs, volunteered to participate and
provided information via mobile phones over a period
of two weeks following purchase of medicine. The
mobile phones were used to provide information on any
ADRs experienced following ingestion of the anti-malar-
ial drug, particularly ACT.
Prior to enrolment in the mobile phone ADR moni-
toring, the objective was explained to each of subjects
after drug purchase was completed by a member of the
study team and informed consent obtained.
The mobile phone number of the participant was
obtained on permission and entered into a registration
form. One member of the study team called the mobile
number to validate correctness of entry and connectiv-
ity. A series of questions were prepared to inquire about
any complaint or reactions observed by the subjects to
whom the drug is administered, if adult, or a caregiver
when subject is a child. Three of the investigators (SB,
TA, AM) were involved in the documentation of any
complaints or observations following drug use. Each
participant is called from mobile phone designated for
the exercise by a member of the study team. The parti-
cipants mobile phones were called at specified times to
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record time of use of drug and 6-hourly for the first
three days and 24 hourly from day 3 to day 14. All com-
plaints or observations were recorded.
Data collection
The pharmacies and medicine stores operate on an
average of 13 hours daily (09.00 hr - 22.00 hr). Drugs
purchased are recorded daily to monitor sales and to
prevent stock-outs. The data on anti-malaria drug sales
was collected daily from the outlets in the 28 days and
transferred into a computer database. Information pro-
vided during mobile phone calls were transferred to
forms designed for the purpose.
Following compilation of mobile phone interaction with
patients or caregivers, each complaint or observation was
examined and determined qualified for ADR. A complaint
or response to inquiries by one of the research team mem-
ber on phone is categorized as ADR from a patient if it
qualifies to be ‘any response to the drug which is noxious
and unintended, and that occurs at doses normally used in
man for prophylaxis, diagnosis, or therapy of diseases or
modification of physiological function’; and an adverse
event if ‘any untoward medical occurrence present in a
patient administered the medicine and which does not
necessarily have to have causal relation with the treatment’.
Data entry and analysis
Generic names, brand names (if possible), pharmacologi-
cal classifications, collection centre, date of collection
and day of study (0-27 days) were entered into a Data-
base. The data generated were analysed using SPSS ver-
sion 10 for Windows (SPSS Inc, Chicago USA). Chi-
square analysis was used to compare proportions and
linear regression analysis was used to obtain relationship
between responses and duration of follow up for the
monitoring aspect of this study.
Ethics
Ethical approval for the study was obtained from the
Joint Ethics Committee of the Olabisi Onabanjo Univer-
sity Teaching Hospital and Obafemi Awolowo College
of Health Science, Olabisi Onabanjo University, Sagamu.
Results
The study was carried out between May-September
2010. In the seven drug retail outlets, the distribution of
drugs purchased in this community in the period of the
study is shown in Table 1. Analgesics (15.8%). antibio-
tics (15.2%), vitamin supplements (13.3%), and anti-
malarials (12.4%), respectively, had the highest frequen-
cies of purchased drugs at these retail outlets. A total of
10,581 (87.5%) complete treatment dosages were sold at
the pharmacies, while 1,512 (12.5%) complete treatment
dosages were sold at the PPMS.
Drug sales
Of 10,581 complete treatment dosage drugs purchased
at the pharmacies, 10.7% were anti-malarials. Sales of
anti-malarials at the PPMS were 23.7% of complete
treatment dosages (1,521) sold. The weekly sales of anti-
malarial and other categories of drugs from these outlets
are shown in Table 2. On average, 375 complete treat-
ment dosages of anti-malarial drugs were purchased
weekly.
Types of anti-malarial and frequency of purchase
The various anti-malarial drugs that were available and
frequently purchased from the study drug outlets were
sulphadoxine-pyrimethamine (SP), chloroquine (CQ),
artesunate (ART), artemether-lumefantrine (AL), amo-
diaquine (AQ), quinine (QN), herbal preparations (HP),
halofantrine (HF), and proguanil (PR). Table 3 shows
the distribution of anti-malarial drugs purchased as
complete treatment dosage from the private retail drug
outlets studied. The PPMS recorded higher purchases of
SP (44.5%) and CQ (29.8%) compared to community
pharmacies which had 37.7% and 23.7% for SP and CQ,
respectively. However, artesunate (monotherapy) pur-
chase was higher at community pharmacies compared
with PPMS (18.1% vs. 9.7%, c2 = 13.6, P = 0.0002).
On average, artesunate was the most purchased anti-
malarial at the pharmacies each week of the study per-
iod, but the least purchased at the PPMS. CQ was how-
ever the least purchased at the community pharmacies
while it was the most purchased at the PPMS. The retail
price per dose of anti-malarial drug (Table 4) varied
with CQ being the cheapest and halofantrine, the most
expensive.
Mobile phone for monitoring of adverse drug reaction
100 volunteers (84 women and 26 men) participated in
the toll free mobile phone monitoring of adverse drug
reactions. 54% of the participants had between 6 and 12
years of formal education and 46% of the subjects had
Table 1 Distribution of drugs purchased in the 4 weeks
of drug surveillance in the retail outlets studied









* = Purchase of other classes of drugs (e.g antidiabetics, haematinics and
hormonal drugs) from these drug outlets ranges from 1 to 269 sales.
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more than 12 years of formal education (post-secondary
school), 5% of them were healthcare providers (nurses
or doctors). The trend of the responses received showed
that most people responded within the first twenty-four
hours of follow-up. By 96 hours, the level of responses
began to decline (Figure 1) with only few respondents
completing the entire follow up period. No incidence of
unknown ADRs was recorded and neither was there any
increase in the frequency of known ADRs during the
period of monitoring.
Discussion
Exposure to anti-malarial drugs as a result of chemopro-
phylaxis or treatment of the infection and choice of
drug depend on the clinical judgment of the physician,
treatment policy, availability or cost. The adoption of
ACT for malaria treatment and increasing access to this
class of anti-malarial drugs offer an opportunity to eval-
uate occurrence of ADRs to these medicines in the lar-
ger population or community [5], Post-marketing
surveillance offers assessment of drug released to the
market in different categories of people, other than
those in whom the drug was tested. ACT is ‘new’ to
anti-malarial therapy in Nigeria and this is additional
reason this study was carried to actively monitor possi-
ble ADRs over an extended period.
Data from this study indicate that medicines in gen-
eral are purchased more from pharmacies compared to
PPMS. However, a high volume of anti-malarial drugs
(23.7%) is purchased at the PPMS. This implies that
people in the study area, prefer PPMS as the first point
of contact for anti-malarials than the pharmacies. Since
the Alma Ata Declaration recognized the Primary
Health Care (PHC) centres as positioned to be the first
contact to individual, family and community, the fre-
quency of visit of the people studied on PPMS for anti-
malarials may suggest that the primary function of the
PHC is not optimized in the study area. The centres are
either underutilized or not easily accessible. The number
of PPMS (128) and community pharmacies (13) in the
community is a strong indicator of the challenges of
PHC programme. PPMS appear more accessible given
the high purchase rate for anti-malarial drugs recorded
in this study and may be considered viable units for
intervention programmes for malaria control in endemic
areas, where PPMS exist. Negligence of these drug retail
outlets may in turn, increase the risk of incorrect dos-
ing, inappropriate treatment, impacting negatively on
drug safety [11].
The large volume of analgesics may suggest the prob-
ability that most people at the point of purchasing anti-
malarials also buy analgesics to relief the symptoms of
malaria, which include fever and arthralgia. The obser-
vation during the study showed that over 50% of those
purchasing anti-malarial drugs also bought analgesics.
Table 2 Complete treatment dosages of anti-malarial drugs purchased per week during the active drug surveillance in
the retail outlets
Weeks Anti-malarials Antibiotics Analgesics Vitamins Total drug
dosage consumed
Percentage (%)
1 434 443 476 455 3088 25.5
2 468 454 530 427 3208 26.6
3 365 556 432 431 3356 27.8
4 233 384 478 299 2441 20.2
Table 3 The distribution of anti-malarial drugs purchased
(in packs of a complete treatment dosage) from the
private retail drug outlets studied








430 (37.7) 160 (44.6)
Chloroquine 271(23.7) 107 (29.8)
Artesunate 207(18.1) 35 (9.7)
Artemether-Lumefantrine 117(10.3) 33 (9.2)
Amodiaquine 75 (6.6) 24 (6.7)
Quinine 28 (2.4) 0 (0)
Herbal preparations 7 (0.6) 0 (0)
Halofantrine 2 (0.1) 1 (0.2)
Proguanil 3 (0.2) 0 (0)
PPMS- Patent and Proprietary Medicine Stores
Table 4 Cost of anti-malarial drugs at the time of the
present study in the retail outlets
S/N DRUGS PRICES
NAIRA (N) DOLLAR ($)
1 Sulphadoxine-pyrimethamine 140 0.9
2 Chloroquine 50 0.3
3 Artesunate 280 1.9
4 Artemether-Lumefantrine 700 4.7
5 Amodiaquine 150 1
6 Quinine 90 0.6
7 Herbal preparations 450 3
8 Halofantrine 1,150 7.7
9 Proguanil 500 3.3
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The frequency of purchase of anti-malarials in com-
munities will differ greatly and may influence serious
ADRs, such as allergic and alveolitis. Despite continuing
education by the Federal Ministry of Health, SP and CQ
use still remains high despite widespread resistance
reported in the area of study [12]; indicating that
although ACT is the recommended first line treatment
for malaria, the official malaria treatment policy is yet to
be fully practiced in the study community, Similar stu-
dies conducted in other malaria endemic areas in Africa
also show that continued use of ineffective anti-malarial
drugs, especially due to poverty, remain a challenge
[13,14]. It will, therefore, be necessary to improve strate-
gies for the implementation of the policy on treatment
of malaria and encourage the inclusion of community
drug outlets level for policy compliance.
Resistance to CQ and failure of mono therapy in many
endemic countries led to a widespread promotion of
ACT [15]. Nevertheless, its adoption appears compro-
mised within the study area with only 10% purchase
rate for ACT. This may be due to the cost of the arte-
misinins being more expensive than the older anti-
malarials, either as artesunate monotherapy or as a
combination [15]. Thus the cost of ACT may compro-
mise effective treatment of malaria in poor countries
with high malaria intensity. The relatively high cost of
ACT in spite of huge financial and logistic commit-
ments to intervention programmes from donor agencies
remains an enigma.
The monitoring of adverse reactions to these drugs
should be an important component of the health care
system. The challenges of pharmacovigilance in Africa
are not unconnected to the poor reporting structures
and lack of motivation to report. The present study
evaluated the use of mobile phone technology for moni-
toring ADRs, especially knowing that the exposure to
antimalarial is relatively high in the community. Finding
from the study showed that mobile phones offer a prac-
tical means of reporting adverse reaction to anti-malarial
drugs and may be a model of choice in Africa where
mobile telephony penetration and coverage is already
driving innovation in agriculture and commerce [16].
The enthusiasm to report ADRs in the volunteers, who
participated in this study, was highest within 24 hours
and dwindled after 96 h. Improved education or enlight-

























Figure 1 Relationship between responses to toll-free mobile phone calls and time of call during monitoring of adverse drug reactions
to anti-malarial drugs purchased in the retail outlets (r = 0.81, F = 13.7, P = 0.008).
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The aim of this research is to provide “proof of princi-
ple” of an innovative approach to support pharmacovigi-
lance in Africa. With over 60% of Africans, in the cities
and small villages owning mobile phones,[16] it is
expected that response to monitoring ADRs in this part
of the world can be improved.
It is noteworthy that retail sectors do serve as source
of malaria treatment and care, complementary to health
facility [17], however, a major concern in this study is
the high exposure to ineffective anti-malarial drugs at
these drug outlets. Education and monitoring of com-
munity drug outlets by the health authority for compli-
ance may provide a pragmatic approach. Training on
the use of anti-malarials and concept of its PV for these
shop keepers may be an option for improving safety of
anti-malarial drugs and the quality of services rendered
at PPMS. Coupling of the training with appropriate
rewards for good practice may improve their perfor-
mances [18].
Although, there was neither increase in the frequency
of known ADRs or new ADRs detected during the
study, it is important to ensure continuing monitoring
of anti-malarial drugs safety and scale up use of mobile
phone technology to support pharmacovigilance of anti-
malarial drugs.
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